[Federal Register Volume 59, Number 44 (Monday, March 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-5086]


[[Page Unknown]]

[Federal Register: March 7, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Exclusive Patent License

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license in a limited field of use to practice the 
inventions embodied in U.S. Patent Application 07/965,916, entitled 
``Immunization Against Neisseria Gonorrhoea'' to Virus Research 
Institute, Inc. having a place of business at Cambridge, Massachusetts. 
The patent application has been continued, with additional data and 
claims, in U.S. Patent Application 08/145,682, entitled ``Immunization 
Against Neisseria Gonorrhoea and Neisseria Meningitides.'' The patent 
rights in these inventions have been assigned to the United States of 
America.
    The prospective exclusive license will be for the field of vaccines 
against Neisseria Gonorrhoea. It will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within sixty 
days from the date of this published Notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    These inventions relate to novel immunization methods and 
compositions useful in protecting against Neisseria Gonorrhoea and 
Neisseria Meningitides infections. In particular, the invention claims 
parenteral component priming-oral immunization methods and compositions 
of matter useful in practicing these methods.
    The availability of U.S. Patent Application 07/965,916 for 
licensing was published in the April 15, 1993 edition of the Federal 
Register. The availability of U.S. Patent Application 08/145,682 for 
licensing has not previously been published.

ADDRESSES: Requests for a copy of the above identified patent 
application, inquiries, comments and other materials relating to the 
contemplated license should be directed to: Mr. Mark Hankins, J.D., 
Office of Technology Transfer, National Institutes of Health, Box OTT, 
Bethesda, Maryland 20892 (telephone: (301) 496-7735; FAX: (301) 402-
0220). A signed confidentiality agreement will be required to receive 
copies of the patent application. Properly filed competing applications 
for a license filed in response to this notice will be treated as 
objections to the grant of the contemplated license. Only written 
comments and/or applications for a license which are received by the 
NIH Office of Technology Transfer within sixty (60) days of this notice 
will be considered.

    Dated: February 18, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-5086 Filed 3-4-94; 8:45 am]
BILLING CODE 4140-01-M